Xoma Purchases Royalty Rights for Aronora’s Five Preclinical and Clinical Hematology Candidates

 Xoma Purchases Royalty Rights for Aronora’s Five Preclinical and Clinical Hematology Candidates

Xoma Purchases Royalty Rights for Aronora’s Five Preclinical and Clinical Hematology Candidates

Shots:

  • Aronora to receive $6M upfront & $3M upon fulfillment of certain conditions. Xoma to get rights to royalties and 10% of milestone payments associated with five hematology assets from Aronora. The transaction is expected to close within the next 90 days
  • The focus of the transaction is to expand XOMA’s portfolio with the addition of hematological & anti-thrombotic mAbs
  • The five hematological assets include three anti-thrombotic candidates BAY1213790 (P-II) BAY1831865, AB023 (P-II) developed in collaboration with Bayer targeting factor XI/XIa and two other assets AB002 (P-I, thrombin analog) & AB054 (factor XII mAb) for acute cardiovascular events

Click here to read full press release/ article | Ref: Xoma | Image: NIH SBIR

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post